Understanding what causes premenstrual symptoms — and what helps — has come a long way. This 2024 review pulls together the latest research on why PMS and PMDD happen and what treatments work best, offering a helpful big-picture look at the options available.
One of the most interesting takeaways is about a brain chemical called allopregnanolone, which is made from progesterone. Women with PMDD appear to have higher levels of this chemical, and their brains may respond to it differently. Rather than hormone levels themselves being "wrong," it seems the brain's ability to adjust to normal hormonal shifts during the cycle is disrupted — particularly in how it affects a calming brain system called GABA. This helps explain why some women are more sensitive to their monthly hormonal changes than others, and why the condition tends to run in families (twin studies suggest over a 40% chance of developing it if your twin has it).
For treatment, the review confirms that SSRIs (a type of antidepressant) are the most effective first-line option, especially for mood symptoms like irritability and anxiety. Importantly, they work much faster for PMDD than for depression — often within days — and can be taken only during the two weeks before your period. Fluoxetine at low doses showed strong results. For physical symptoms like bloating, breast tenderness, and headaches, a specific birth control pill containing drospirenone and ethinylestradiol (taken on a 24-days-on, 4-days-off schedule) is FDA-approved and well-studied. The review emphasizes that treatment should be personalized based on whether your symptoms are mostly emotional, mostly physical, or both.
Beyond medication, evidence supports cognitive-behavioral therapy, regular exercise (especially yoga), and supplements like calcium, zinc, and B vitamins for milder symptoms. Healthy diet changes — more fruits, vegetables, and fish, less processed food and sugar — may also help. The authors stress that these lifestyle approaches work best alongside medical treatment for more severe cases, and that understanding and support from loved ones matters too.
Key findings
- Global prevalence of PMS is estimated at 47.8%, with severe symptoms (PMDD) affecting 3-8% of women of reproductive age
- Allopregnanolone concentrations and its conversion from progesterone are higher in women with PMDD, suggesting disturbed progesterone metabolism rather than abnormal hormone levels per se
- SSRIs show beneficial effects in 60-90% of PMDD patients (vs 30-40% placebo response), with rapid onset of action within days rather than the typical 3-week delay seen in depression treatment
- Oral contraceptives containing drospirenone 3mg and ethinylestradiol 20mcg (24/4 dosing regimen) are FDA-approved and most effective among hormonal treatments for PMDD, particularly for physical symptoms
- Fluoxetine at doses as low as 10 mg/day during the luteal phase reduced emotional PMS symptoms by more than 40% in 70% of participants in a pilot study
- Non-pharmacological approaches including CBT, yoga, aerobic exercise, and supplementation with zinc, calcium, vitamin D, and B vitamins show evidence of reducing PMS symptom severity
Methods, briefly
Narrative review of published literature on PMS/PMDD etiology and treatment. The authors examined studies on SSRIs (fluoxetine, sertraline, paroxetine, escitalopram, citalopram), hormonal agents (oral contraceptives, GnRH agonists, ulipristal acetate, sepranolone), herbal treatments (VAC, saffron, curcumin, St. John's wort), supplementation, CBT, exercise, and surgical approaches. Detailed tables summarizing individual study designs, sample sizes, outcomes, and limitations were provided. The review is explicitly stated as non-systematic.
Limitations to keep in mind
- Not a systematic review — the authors acknowledge they may not have covered all studies
- Many of the underlying studies reviewed had small sample sizes, short durations (often only 2-3 menstrual cycles), and high placebo response rates (27-53% for PMDD studies)
- Most herbal treatment studies had significant methodological flaws including absence of placebo groups, subjective measurement methods, and student-only samples
- Limited head-to-head comparisons between different treatment approaches
- The review did not employ formal risk-of-bias assessment or meta-analytic methods
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.